Valuation: Pulmonx Corporation

Market Cap 59.13M 51.68M 47.68M 43.95M 82.84M 5.69B 84.68M 570M 224M 2.79B 222M 217M 9.6B P/E 2026 *
-1.23x
P/E 2027 * -1.34x
Enterprise Value 59.13M 51.68M 47.68M 43.95M 82.84M 5.69B 84.68M 570M 224M 2.79B 222M 217M 9.6B EV / Sales 2026 *
0.65x
EV / Sales 2027 * 0.6x
Free-Float
95.11%
Yield 2026 *
-
Yield 2027 * -
1 day-3.45%
1 week-9.09%
Current month+7.69%
1 month+9.38%
3 months-4.76%
6 months-20.90%
Current year-36.65%
1 week 1.36
Extreme 1.36
1.6
1 month 1.23
Extreme 1.23
1.6
Current year 1.13
Extreme 1.13
2.39
1 year 1.13
Extreme 1.13
3.88
3 years 1.13
Extreme 1.13
14.84
5 years 1.13
Extreme 1.13
45.49
10 years 1.13
Extreme 1.13
69.48
Manager TitleAgeSince
Chief Executive Officer 64 27/10/2025
Director of Finance/CFO 53 01/05/2019
Chief Tech/Sci/R&D Officer - 01/03/2020
Director TitleAgeSince
Director/Board Member 72 01/02/2007
Director/Board Member 64 18/12/2014
Chairman 66 01/10/2019
Date Insider Type Main position Quantity % Market Cap.
6/5/26 A Free

Director

40,000 0.0947%
6/5/26 A Free

Director

40,000 0.0947%
6/5/26 A Free

Director

40,000 0.0947%
Change 5-day change 1-year change 3-year change Capi.($)
-3.45%-9.09%-55.56%-89.35% 59.13M
-0.40%+0.07%+38.17%+1.20% 12.52B
+10.14%+11.94%+15.79%+20.31% 6.57B
+2.91%-0.11%+55.48%+29.66% 5.83B
+6.61%+10.73% - - 4.75B
-2.77%-0.34%-29.59%+15.87% 4.25B
-2.01%+4.84%-22.35%-22.76% 4.02B
-3.05%-2.33%-0.62%-59.82% 1.84B
-3.31%-6.97%-4.51%+246.89% 1.8B
0.00%+0.66%+59.44%-3.17% 1.56B
Average +0.47%+0.71%+6.25%+15.43% 4.32B
Weighted average by Cap. +1.81%+2.82%+20.02%+16.19%

Financials

2026 *2027 *
Net sales 90.77M 79.33M 73.2M 67.47M 127M 8.74B 130M 875M 344M 4.28B 341M 333M 14.74B 98.07M 85.71M 79.09M 72.9M 137M 9.44B 140M 945M 372M 4.63B 368M 360M 15.92B
Net income -47.97M -41.92M -38.69M -35.66M -67.21M -4.62B -68.7M -462M -182M -2.26B -180M -176M -7.79B -44.58M -38.95M -35.95M -33.13M -62.45M -4.29B -63.84M -430M -169M -2.1B -167M -164M -7.24B
Net Debt - -
Logo Pulmonx Corporation
Pulmonx Corporation is a commercial-stage medical technology company. The Company provides minimally invasive treatments for chronic obstructive pulmonary disease (COPD). The Company’s Zephyr Endobronchial Valve, Chartis Pulmonary Assessment System, LungTraX Platform, and StratX Lung Analysis Report are designed to assess and treat patients with severe emphysema/COPD. The LungTraX Platform is a cloud-based quantitative CT (QCT) analysis service that provides physicians with multiple products, LungTraX Connect, to improve workup efficiency, LungTraX Detect, to enable patient identification and an easy-to-read StratX Lung report that it designed for its solution that includes information on emphysema destruction, fissure completeness and lobar volume to help identify target lobes for treatment with Zephyr Valves. The Chartis System is a proprietary balloon catheter and console system with flow and pressure sensors designed to assess the presence of collateral ventilation.
Employees
296
Date Price Change Volume
17/07/26 $1.400 -3.45% 108,350
16/07/26 $1.450 +0.69% 181,150
15/07/26 $1.440 -2.70% 112,144
14/07/26 $1.480 +1.37% 191,629
13/07/26 $1.460 -5.19% 270,027
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
BBB
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
5
Last Close Price
1.400USD
Average target price
3.400USD
Spread / Average Target
+142.86%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. LUNG Stock